No abstract

No abstract

A key component of improving human-computer interaction is through the matching of users with their preferred computer interfaces and interaction styles. Understanding the users better would result in a customized gaming experience, leading to sustained user engagement. In this paper, we develop an alternative tool to aid in the measurement of the D.I.S.C. personality styles of users in the form of an interactive game. Through this game, we aim to predict the personality type of the gamer, from which invaluable insights about each type of gamer can be elicited.

Background Sofosbuvir/Velpatasvir/Voxilaprevir (SOF/VEL/VOX) was approved as salvage therapy for NS5A-experienced hepatitis C virus (HCV) infected patients. However, the realworld data of SOF/VEL/VOX remained limited in Asia. We aim to analyse the real-world efficacy and safety of SOF/ VEL/VOX among NS5A-experienced Asian HCV patients. Methods This was a cross-sectional, multicenter, international study assessing the efficacy of retreatment using SOF/VEL/ VOX among Asian HCV patients with prior direct-acting antiviral (DAA) failure. Our primary aim is sustained-virological response 12 weeks after completion of treatment (SVR12). Data on safety and treatment outcomes were also recorded. Results Nineteen patients were included from 5 hospitals. Median age was 57, 84% were male, 47% were ex-IVDU and 63% had liver cirrhosis. Among 12 patients with liver cirrhosis, 75% were Child-Turcotte-Pugh Class A and 25% were Class B. Commonest genotype (GT) requiring retreatment using SOF/VEL/VOX was GT3 (68%), followed by GT1, GT2 and GT6 (11%). Prior DAA include SOF/VEL (79%), HAR-VONI (11%), Glecaprevir/Pibrentasvir (5%) and Daclatasvir/ Asunaprevir (5%).The overall SVR12 rate by intention-to-treat and per-protocol (PP) analysis was 84.1% and 94.1%, respectively. Two patients were demised before treatment completion from HCC progression and septic shock, and were excluded from PP analysis. The SVR12 was not significantly different in patients with GT3 (GT3: 91%, non-GT3: 100%, p=0.647). The only patient with virological failure had compensated GT3 cirrhosis with portal hypertension after completed 12 weeks of SOF/ VEL/VOX. Significant improvement observed in median serum ALT, AST and bilirubin following SVR12 (p<0.05) Conclusions In this real-world international study, we found that SOF/VEL/VOX is an efficacious and safe salvage regimen among NS5A-experienced HCV patients in Asia.